<- Go Home
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company has a strategic alliance with University of Alabama for the development of ai² future labs program. The company was incorporated in 2020 and is based in Matawan, New Jersey.
Market Cap
$28.7M
Volume
128.8K
Cash and Equivalents
$7.0M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$4.03
52 Week Low
$1.37
Dividend
N/A
Price / Book Value
3.51
Price / Earnings
-4.29
Price / Tangible Book Value
3.51
Enterprise Value
$22.2M
Enterprise Value / EBITDA
N/A
Operating Income
-$5.1M
Return on Equity
144.99%
Return on Assets
-69.29
Cash and Short Term Investments
$7.0M
Debt
$500.1K
Equity
$8.2M
Revenue
N/A
Unlevered FCF
-$3.3M
Sector
Biotechnology
Category
N/A